Which has higher valuation and earnings, HROW or BLTE?

Harrow has higher revenue and earnings than Belite Bio. Harrow is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harrow $272.30M 5.87 -$5.14M -$0.41 N/A Belite Bio N/A N/A -$77.61M -$2.53 N/A

Is HROW or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Harrow -5.57% 19.59% 2.26% Belite Bio N/A -13.14% -12.88%

Does the media prefer HROW or BLTE?

In the previous week, Belite Bio had 1 more articles in the media than Harrow. MarketBeat recorded 4 mentions for Belite Bio and 3 mentions for Harrow. Harrow's average media sentiment score of 1.08 beat Belite Bio's score of -0.03 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer HROW or APGE?

In the previous week, Apogee Therapeutics had 6 more articles in the media than Harrow. MarketBeat recorded 9 mentions for Apogee Therapeutics and 3 mentions for Harrow. Apogee Therapeutics' average media sentiment score of 1.45 beat Harrow's score of 1.08 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is HROW or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Harrow -5.57% 19.59% 2.26% Scholar Rock N/A -163.52% -96.67%

Does the media prefer HROW or SRRK?

In the previous week, Scholar Rock had 1 more articles in the media than Harrow. MarketBeat recorded 4 mentions for Scholar Rock and 3 mentions for Harrow. Scholar Rock's average media sentiment score of 1.49 beat Harrow's score of 1.08 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, HROW or CGON?

Harrow has higher revenue and earnings than CG Oncology. Harrow is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harrow $272.30M 5.87 -$5.14M -$0.41 N/A CG Oncology $4.04M 1,333.48 -$160.99M -$2.33 N/A

Is HROW or CGON more profitable?

CG Oncology has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Harrow -5.57% 19.59% 2.26% CG Oncology N/A -23.33% -22.24%

Does the media prefer HROW or CGON?

In the previous week, CG Oncology had 3 more articles in the media than Harrow. MarketBeat recorded 6 mentions for CG Oncology and 3 mentions for Harrow. CG Oncology's average media sentiment score of 1.21 beat Harrow's score of 1.08 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, HROW or GRFS?

Grifols has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harrow $272.30M 5.87 -$5.14M -$0.41 N/A Grifols $8.51B 0.59 $454.82M $0.19 38.95

Is HROW or GRFS more profitable?

Grifols has a net margin of 5.54% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Grifols' return on equity. Company Net Margins Return on Equity Return on Assets Harrow -5.57% 19.59% 2.26% Grifols 5.54% 6.21% 2.39%

Does the media prefer HROW or GRFS?

In the previous week, Harrow had 1 more articles in the media than Grifols. MarketBeat recorded 3 mentions for Harrow and 2 mentions for Grifols. Harrow's average media sentiment score of 1.08 beat Grifols' score of 0.66 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Harrow (HROW) Competitors

$42.87 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$42.46 -0.41 (-0.96%)

As of 06/18/2026 07:59 PM Eastern

Compare

HROW vs. BLTE, APGE, SRRK, CGON, and GRFS

Should you buy Harrow stock or one of its competitors? MarketBeat compares Harrow with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Harrow include Belite Bio (BLTE), Apogee Therapeutics (APGE), Scholar Rock (SRRK), CG Oncology (CGON), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.

How does Harrow compare to Belite Bio?

Harrow (NASDAQ:HROW) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Harrow presently has a consensus price target of $69.43, indicating a potential upside of 61.95%. Belite Bio has a consensus price target of $203.00, indicating a potential upside of 38.93%. Given Harrow's stronger consensus rating and higher possible upside, research analysts plainly believe Harrow is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Harrow has higher revenue and earnings than Belite Bio. Harrow is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	5.87	-$5.14M	-$0.41	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Belite Bio has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
Belite Bio	N/A	-13.14%	-12.88%

72.8% of Harrow shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 12.8% of Harrow shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Harrow has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.24, indicating that its stock price is 224% less volatile than the broader market.

In the previous week, Belite Bio had 1 more articles in the media than Harrow. MarketBeat recorded 4 mentions for Belite Bio and 3 mentions for Harrow. Harrow's average media sentiment score of 1.08 beat Belite Bio's score of -0.03 indicating that Harrow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Harrow beats Belite Bio on 11 of the 15 factors compared between the two stocks.

How does Harrow compare to Apogee Therapeutics?

Harrow (NASDAQ:HROW) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

72.8% of Harrow shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 12.8% of Harrow shares are held by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Apogee Therapeutics had 6 more articles in the media than Harrow. MarketBeat recorded 9 mentions for Apogee Therapeutics and 3 mentions for Harrow. Apogee Therapeutics' average media sentiment score of 1.45 beat Harrow's score of 1.08 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harrow has higher revenue and earnings than Apogee Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	5.87	-$5.14M	-$0.41	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

Harrow currently has a consensus price target of $69.43, suggesting a potential upside of 61.95%. Apogee Therapeutics has a consensus price target of $114.56, suggesting a potential upside of 26.76%. Given Harrow's higher possible upside, analysts plainly believe Harrow is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Apogee Therapeutics	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74

Apogee Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Harrow has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

Summary

Apogee Therapeutics beats Harrow on 10 of the 16 factors compared between the two stocks.

How does Harrow compare to Scholar Rock?

Harrow (NASDAQ:HROW) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Scholar Rock has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
Scholar Rock	N/A	-163.52%	-96.67%

Harrow has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

In the previous week, Scholar Rock had 1 more articles in the media than Harrow. MarketBeat recorded 4 mentions for Scholar Rock and 3 mentions for Harrow. Scholar Rock's average media sentiment score of 1.49 beat Harrow's score of 1.08 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harrow currently has a consensus target price of $69.43, suggesting a potential upside of 61.95%. Scholar Rock has a consensus target price of $56.00, suggesting a potential upside of 18.32%. Given Harrow's higher probable upside, equities analysts plainly believe Harrow is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Harrow has higher revenue and earnings than Scholar Rock. Harrow is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	5.87	-$5.14M	-$0.41	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

72.8% of Harrow shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 12.8% of Harrow shares are held by company insiders. Comparatively, 13.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Scholar Rock beats Harrow on 10 of the 16 factors compared between the two stocks.

How does Harrow compare to CG Oncology?

Harrow (NASDAQ:HROW) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Harrow has higher revenue and earnings than CG Oncology. Harrow is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	5.87	-$5.14M	-$0.41	N/A
CG Oncology	$4.04M	1,333.48	-$160.99M	-$2.33	N/A

CG Oncology has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
CG Oncology	N/A	-23.33%	-22.24%

Harrow has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

72.8% of Harrow shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 12.8% of Harrow shares are held by company insiders. Comparatively, 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, CG Oncology had 3 more articles in the media than Harrow. MarketBeat recorded 6 mentions for CG Oncology and 3 mentions for Harrow. CG Oncology's average media sentiment score of 1.21 beat Harrow's score of 1.08 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harrow presently has a consensus price target of $69.43, indicating a potential upside of 61.95%. CG Oncology has a consensus price target of $81.73, indicating a potential upside of 33.80%. Given Harrow's higher probable upside, research analysts clearly believe Harrow is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Harrow and CG Oncology tied by winning 8 of the 16 factors compared between the two stocks.

How does Harrow compare to Grifols?

Harrow (NASDAQ:HROW) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Grifols has a net margin of 5.54% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
Grifols	5.54%	6.21%	2.39%

In the previous week, Harrow had 1 more articles in the media than Grifols. MarketBeat recorded 3 mentions for Harrow and 2 mentions for Grifols. Harrow's average media sentiment score of 1.08 beat Grifols' score of 0.66 indicating that Harrow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harrow has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Grifols has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

Grifols has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	5.87	-$5.14M	-$0.41	N/A
Grifols	$8.51B	0.59	$454.82M	$0.19	38.95

72.8% of Harrow shares are held by institutional investors. 12.8% of Harrow shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Harrow currently has a consensus target price of $69.43, indicating a potential upside of 61.95%. Grifols has a consensus target price of $10.00, indicating a potential upside of 35.14%. Given Harrow's stronger consensus rating and higher possible upside, equities analysts clearly believe Harrow is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Harrow beats Grifols on 9 of the 16 factors compared between the two stocks.

Get Harrow News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HROW vs. The Competition

Export

Metric	Harrow	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.60B	$2.98B	$6.42B	$12.59B
Dividend Yield	N/A	1.78%	2.68%	5.81%
P/E Ratio	-104.56	18.67	24.56	24.44
Price / Sales	5.87	455.43	553.91	122.27
Price / Cash	49.60	56.42	45.07	55.09
Price / Book	30.40	4.04	10.80	6.58
Net Income	-$5.14M	$75.79M	$3.57B	$337.17M
7 Day Performance	13.89%	0.38%	0.72%	0.83%
1 Month Performance	30.07%	-0.14%	0.41%	2.25%
1 Year Performance	39.82%	26.02%	29.34%	36.14%

Harrow Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HROW Harrow	4.4621 of 5 stars	$42.87 flat	$69.43 +62.0%	+39.8%	$1.60B	$272.30M	N/A	180	Positive News
BLTE Belite Bio	2.9156 of 5 stars	$144.24 +4.4%	$203.00 +40.7%	+141.6%	$5.54B	N/A	N/A	10	Insider Trade
APGE Apogee Therapeutics	3.4276 of 5 stars	$86.19 -2.4%	$114.56 +32.9%	+115.4%	$5.47B	N/A	N/A	91	Positive News
SRRK Scholar Rock	2.7383 of 5 stars	$45.92 +3.9%	$56.00 +22.0%	+39.0%	$5.29B	N/A	N/A	140	Positive News Analyst Forecast
CGON CG Oncology	3.1594 of 5 stars	$59.55 0.0%	$81.73 +37.2%	+139.1%	$5.25B	$4.04M	N/A	61	News Coverage Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HROW) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harrow (HROW) Competitors